Utilising Solubility Modelling to Reduce the R&D Timeline
Contributor:
Pharma IQ
Posted: 12/24/2010 12:00:00 AM EST | 0
Posted: 12/24/2010 12:00:00 AM EST | 0
|
Reducing the time drugs take to get to market is a key focus for a pharmaceutical industry facing the expiry of patents on blockbuster products and the subsequent influx of generics.
Poor solubility is one of the ever-present factors delaying drug development and it would appear current industry conditions have led pharmaceutical companies to step up investment to combat this.
Indeed, improving so...
-
Pharma Bytes: Interview with Per Holm of Lundbeck -
Adopting Single-Use Systems in Biomanufacturing -
Freeze-Drying and Optimising Formulation Development for Biologicals -
Top 3 Best Practices for Complying with the Development Safety Update Report (DSUR) -
Top 3 Tips for Developing a Globally Applicable Labelling Strategy -
Clinical Trials in Egypt and the MENA Region -
Functional Foods: Addressing Claims & Labelling Concerns -
Saudi Arabia's Plastic Packaging Market Poised for Success -
Regulators Adapt to Increasingly Globalised Pharmaceutical Industry -
Transportation Will be the Key for Future Biomaterial Market Growth
* = required.
Not a member yet? Sign up
Events of Interest
-
Enhancing the Bioavailability of Low-Solubility Compounds
February 18, 2010
Register Now -
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now -
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!